Trial · NCT00175019
Results by group37
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 37
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change in Serum Urate Levels From Baseline to the Last Visit on Treatment. | Febuxostat 80 mg QD | -46.69 | Standard Deviation 17.43 | percent change from baseline | |
| Percent Change in Serum Urate Levels From Baseline to the Last Visit on Treatment. | Febuxostat 120 mg QD | -52.99 | Standard Deviation 19.12 | percent change from baseline | |
| Percent Change in Serum Urate Levels From Baseline to the Last Visit on Treatment. | Allopurinol QD | -32.17 | Standard Deviation 17.71 | percent change from baseline | |
| Percent Change From Baseline in Primary Tophus Size at Month 12 for Subjects With Palpable Tophi Measured at Baseline. | Febuxostat 80 mg QD | -82 | Inter-Quartile Range -100 to -40 | percent change from baseline | |
| Percent Change From Baseline in Primary Tophus Size at Month 12 for Subjects With Palpable Tophi Measured at Baseline. | Febuxostat 120 mg QD | -79 | Inter-Quartile Range -100 to -26 | percent change from baseline | |
| Percent Change From Baseline in Primary Tophus Size at Month 12 for Subjects With Palpable Tophi Measured at Baseline. | Allopurinol QD | -56 | Inter-Quartile Range -100 to -16 | percent change from baseline | |
| Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 1. | Febuxostat 80 mg QD | 80.8 | percentage of subjects | ||
| Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 1. | Febuxostat 120 mg QD | 87.0 | percentage of subjects | ||
| Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 1. | Allopurinol QD | 46.0 | percentage of subjects | ||
| Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 12. | Febuxostat 80 mg QD | 88.9 | percentage of subjects | ||
| Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 12. | Febuxostat 120 mg QD | 86.3 | percentage of subjects | ||
| Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 12. | Allopurinol QD | 82.2 | percentage of subjects | ||
| Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 24. | Febuxostat 80 mg QD | 89.3 | percentage of subjects | ||
| Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 24. | Febuxostat 120 mg QD | 87.2 | percentage of subjects | ||
| Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 24. | Allopurinol QD | 78.6 | percentage of subjects | ||
| Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 36. | Febuxostat 80 mg QD | 90.8 | percentage of subjects | ||
| Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 36. | Febuxostat 120 mg QD | 91.5 | percentage of subjects | ||
| Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 36. | Allopurinol QD | 90.0 | percentage of subjects | ||
| Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Last Visit on Treatment. | Febuxostat 80 mg QD | 70.8 | percentage of subjects | ||
| Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Last Visit on Treatment. | Febuxostat 120 mg QD | 82.0 | percentage of subjects |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00175019/results